Immunome is a biotechnology company with a growing pipeline of novel antibody therapeutics fueled by the human immune system. Our unique and powerful approach leverages deep interrogation of the most “highly-educated” B cells from patients who have already learned how to fight off their disease. Our proprietary technology platform enables the simultaneous discovery of novel antigens (targets) and the patient-derived, native antibodies that bind to those targets with high affinity. We systematically evaluate the therapeutic potential of these antibodies when they engage the targets, especially in areas of high unmet need, such as cancer and infectious diseases.